cyrilzakka/clinical-trials huggingface dataset:
The Feasibility of a Radiological Score Based on CT Signs for Recognizing Salvageable Bowel in Acute Mesenteric Ischemia

Computed tomography (CT) is the standard modality for scanning patients with critical acute abdominal conditions, including suspected acute mesenteric ischemia (AMI). CT imaging can potentially differentiate between reversible and irreversible ischaemic damage of the bowel. This moment is pivotal in selecting the treatment strategy for AMI - in the absence of irreversible damage; reperfusion therapy can preserve intestinal viability, thereby avoiding the need for bowel resection. The present study tests the hypothesis that combining several symptoms may enhance the diagnostic performance of CT scanning in detecting salvageable bowel in patients with AMI. This study is an ancillary component of the AMESI study (Clinical Trials: NCT05218863) - a prospective, multicentre observational study aimed at identifying the incidence and describing the outcomes of acute mesenteric ischemia (AMI) in adult hospitalized patients. The ultimate purpose of the present study is to create a computed tomography-based radiological score for the assessment of bowel viability in patients with AMI.


Eligibility Criteria:
Inclusion Criteria:

* Participant in AMESI study
* confirmed or suspected acute mesenteric ischaemia
* CT scan of the entire abdominal cavity / full body using intravenous contrast media is available

Exclusion Criteria:

* Scans without the use of an intravenous contrast media or those covering only a partial area of the abdomen will be excluded.
Effect of Sodium Bicarbonate, Saline and Black Mulberry Syrup on Degree of Oral Mucositis in Children Receiving Chemotherapy

This study was planned as a randomized controlled experimental study in order to compare the effects of oral care with saline and black mulberry syrup in addition to sodium bicarbonate on oral mucositis level in children aged 6-18 years receiving chemotherapy.

Oral mucositis, also known as stomatitis, is the most common complication of cancer treatment. Mucositis affects the patient's nutrition, daily functions, and quality of life, may compromise the ability to tolerate scheduled therapy. For this reason, the children to be included in the study will be randomly divided into three groups. Sodium bicarbonate, which is the routine care in the clinic, will be administered to the control group, and to the intervention groups, saline in addition to the routine care and black mulberry syrup will be applied in addition to the routine care. Data will be collected according to Patient Information Form, International Child Mucositis Assessment Scale (ChIMES), World Health Organization Mucositis Classification and neutrophil counts. Oral care will be applied to the groups 4 times a day for 14 days. The International Child Mucositis Rating Scale (ChIMES), World Health Organization Mucositis Classification and neutrophil counts will be evaluated by the researchers on the 1st, 2nd, 4th, 8th and 16th days.

Eligibility Criteria:
Inclusion Criteria:

* The willingness of the family and the child to participate in the study
* Parent and child have separately informed written consent form
* Be between 6-18 years old
* Receiving chemotherapy and being hospitalized for chemotherapy treatment
* Being fed orally

Exclusion Criteria:

* Oral mucositis in the first intraoral evaluation
* Having diabetes
* Receiving radiotherapy
* Having a surgical procedure in the mouth and jaw area
* Receiving steroid therapy during chemotherapy treatment
* Using a method other than the methods used in the study to protect the oral mucous membrane throughout the study
The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine

The purpose of this study is to evaluate the safety and effectiveness of Hyeonggaeyeongyo-Tang for chronic rhinitis according to pattern identification in Korean medicine.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who are diagnosed by moderate level of chronic rhinitis for more than 8 weeks

   * At least one of the following conditions: Nasal congestion, rhinorrhea, sneeze, pruritus
   * At least one of the following Moderate abnormality conditions: sleep disturbance; daily activity, physical exercise, leisure activity limitations; work/school work limitations; discomfort with several symptoms
2. Age between 19 and 65 years
3. Able to dialogue
4. Agree with informed consent

Exclusion Criteria:

1. Patients who are taken one of the following drugs for treating rhinitis or acute upper respiratory infections etc

   * Drugs which determined to have negative effect on symptoms of rhinitis or skin prick test (oral or nasal)

     * Short acting anti-histamines / H1 blockers (drug use within lase 1 week)

       * Long acting anti-histamines / H1 blockers (drug use within lase 2 week)

         * Corticosteroids (drug use within lase 1 month) ④ Anti-cholinergic drug (drug use within lase 1 week)

           * Anti-leukotriene drug (drug use within lase 1 week)

             * Decongestants (drug use within lase 1 week) ⑦ Tricyclic antidepressants, phenothiazines (drug use within lase 2 week) ⑧ Non-steroidal analgesics (drug use within lase 1 week) ⑨ Drugs that is judged to be inappropriate for the trial by the researchers
2. Used Korean medicine for treating rhinitis within last 7 days
3. Patients who has severe disease, such as malignant tumor, severe dyslipidemia, liver or kidney dysfunction, anemia, active pulmonary tuberculosis, infection or systemic disease etc
4. Presence of internal nasal obstruction or nasal deformities or history of nasal surgery within 2 months
5. History of active respiratory disease(ex. asthma)
6. Hypertension or Diabetes
7. Experienced immunotherapy or systemic steroid treatments within last 3 months
8. Experienced drug allergic reactions
9. Experienced anaphylactic reactions, during allergen test
10. Female patients who are pregnant or lactating or have the chances of pregnancy
11. Patients who are participated other clinical trials within last 1 month
12. Patients who are unable to participate the trial (paralysis, severe mental or psychological illness, dementia, drug addiction, unable to make to participate in the trial, severe visual or auditory dysfunction, unable to visit hospital regularly, unable to communicate through spoken or written Korean etc)
13. Patients who are judged to be inappropriate for the clinical study by the researchers
Quadratus Lumborum Block for Lumbar Spinal Surgery

Spine surgery in thoracolumbar region is one of the most common surgeries performed for the treatment of leg and back pain. Pain management is especially important for these patients since chronic pain often occurs after surgery. Severe pain may occur at postoperative period in patients following lumbar disc herniation (LDH) operation. Postoperative effective pain treatment provides early mobilization and shorter hospital stay, thus complications due to hospitalization such as infection and thromboembolism may be reduced.

Ultrasound-guided quadratus lumborum block (QLB) is a fascial plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

The aim of this study is to evaluate the efficacy of US-guided QLB for postoperative analgesia management after lumbar disc herniation-laminectomy surgery. The primary aim is to evaluate postoperative pain scores (VAS), the secondary aim is to evaluate use of rescue analgesia and adverse effects (allergic reaction, nausea, vomiting).

Spine surgery in thoracolumbar region is one of the most common surgeries performed for the treatment of leg and back pain. Pain management is especially important for these patients since chronic pain often occurs after surgery. Severe pain may occur at postoperative period in patients following lumbar disc herniation (LDH) operation. Postoperative effective pain treatment provides early mobilization and shorter hospital stay, thus complications due to hospitalization such as infection and thromboembolism may be reduced.

Opioids are one of the most preferred drugs among the analgesic agents. Parenteral opioids are generally performed for patients after surgery. However opioids have undesirable adverse events such as nausea, vomiting, itching, sedation and respiratory depression (opioid-related adverse events).

Various methods may be performed to reduce the use of systemic opioids and for effective pain treatment. US-guided interfascial plane blocks have been used increasily due to the advantages of ultrasound in anesthesia practice. Ultrasound-guided quadratus lumborum block (QLB) is a fascial plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.

The aim of this study is to evaluate the efficacy of US-guided QLB for postoperative analgesia management after lumbar disc herniation-laminectomy surgery. The primary aim is to evaluate postoperative pain scores (VAS), the secondary aim is to evaluate use of rescue analgesia and adverse effects (allergic reaction, nausea, vomiting).

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists (ASA) classification I-II
* Scheduled for lumbar disc herniation surgery under general anesthesia

Exclusion Criteria:

* Bleeding diathesis
* Receiving anticoagulant treatment
* Known local anesthetics and opioid allergy
* Infection of the skin at the site of the needle puncture
* Pregnancy or lactation
* Patients who do not accept the procedure
Comparison of Different Materials Contribution to Implants Stability

The investigators will use two types of material(PRF-Xenograft) in the buccal gap after immediate dental implant placement. The study design has three groups PRF, graft, and control group. The patients will randomly be assigned to groups by envelop method. The resonance frequency analysis device(Osstell) will be used to measure primary and secondary stabilization. Then the investigators will evaluate each materials' contribution to stability.

Pre-op and 9th month Post-op CBCTs will evaluate about bone loss in mesial-distal and horizontal dimensions.


Eligibility Criteria:
Inclusion Criteria:

* medically healthy,
* only one maxillary aesthetic region(incisors or premolars) tooth which has two adjacent teeth is indicated for extraction.
* intact buccal socket walls
* the gap between buccal socket wall to implant sholder at least 2 mm.

Exclusion Criteria:

* relevant tooth has more than one root,
* smoking,
* alcohol abuse,
* pregnancy,
* immune-suppressive patients,
* any systemic disease.
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.

Primary Objective:

\>To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c \<= 7% without confirmed nocturnal hypoglycaemia in each treatment group.

Secondary Objectives:

* Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and after each period of treatment.
* Incidence of confirmed symptomatic and nocturnal hypoglycemia.
* Incidence of confirmed severe hypoglycemia (\< 36mg/dL or need of help to recover). \>Weight variation for each period of treatment.
* Creatinine clearance at baseline and after each period of treatment.
* Overall safety: Incidence of adverse events.


Eligibility Criteria:
Inclusion criteria:

* Type 2 diabetes and renal failure in use of NPH regular insulin or fast-acting analog and HbA1c \>= 8%.
* Albuminuria or microalbuminuria diabetic retinopathy.
* Creatinine clearance \< 60 mL/min/1,73 m2 and \>30 mL/min/1,73 m2

Exclusion criteria:

* Hypersensibility to insulin glargine or any other component of the insulin formulation.
* Use of investigational medications during the last 12 months or use of any investigational insulin preparation during the last 4 months.
* History of diabetic ketoacidosis or positive GAD antibodies.
* Advanced retinopathy needing laser therapy.
* Diagnosed advanced neuropathy
* Severe hepatic disease or active hepatitis.
* Cardiac failure class III or IV (NYHA).
* Patients on hemodialysis.
* Diagnosed cancer.
* Active infection.
* Current therapy with steroids.
* Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"

A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics after Administration of the "CDFF0318" and "Champix Tab. 1mg (Varenicline tartrate)" in Healthy Male Volunteers


Eligibility Criteria:
Inclusion Criteria:

* Healthy male subjects aged 19 to 45 years
* a body mass index of 18.0-30.0 kg/m2

Exclusion Criteria:

* Subjects with disease history or current disease of clinically significant liver, kidney, nervous system, respiratory system, endocrine system, blood/tumor, urinary system, cardiovascular system, etc.
* Subjects with a history of gastrointestinal diseases or gastrointestinal surgery that may affect the absorption of investigational drugs
* Subjects with a history of hypersensitivity reactions or clinically significant hypersensitivity reactions to drugs containing varenicline and other drugs (ketoprofen, aspirin, antibiotics, etc.)
* Subjects who have an abnormal diet that may affect the absorption, distribution, metabolism, and excretion of the drug, or who eat food that may affect drug metabolism
Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

The purpose of this study is to evaluate how BLI-489 and piperacillin interact when given together to healthy subjects.


Eligibility Criteria:
Inclusion Criteria:

1. Men or women of non-childbearing potential, aged 18 to 50 years of age inclusive at screening.
2. Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight greater than or equal to 50 kg.
3. Healthy as determined by the investigator on the basis of the screening evaluations.
4. Nonsmoker of smoker of fewer than 10 cigarettes per day as determined by history.

Exclusion Criteria:

1. Presence of history of any disorder that may prevent the successful completion of the study.
2. History of drug abuse within 1 year.
Artificial Intelligence and Bone Tomoscintigraphies Achieved With CZT Camera

This study aimed to determine whether the whole-body bone Single Photon Emission Computed Tomography (SPECT) recording times of around 10 minutes, routinely provided by a high-sensitivity 360 degrees cadmium and zinc telluride (CZT) camera, can be further reduced by a deep learning noise reduction (DLNR) algorithm.

This study aimed to determine the extent to which fast whole-body bone-SPECT recording times, routinely obtained with a high-sensitivity 360 degrees CZT-camera and rather low injected activities, can be further reduced using the DLNR algorithm.

Eligibility Criteria:
Inclusion Criteria:

* patients referred to fast whole-body bone single photon emission tomography for detection or follow-up of bone metastasis
Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182

RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.

PURPOSE: This research study is looking at biomarkers in predicting response in patients with advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

OBJECTIVES:

Primary

* To evaluate ERCC1 tumor expression, as measured by IHC, as a predictor of progression-free and overall survival of patients with advanced ovarian epithelial cancer.

Secondary

* To correlate ERCC1 single-nucleotide polymorphisms (C8092A and codon 118) with ERCC1 tumor expression.

OUTLINE: This is a multicenter study.

Blood and paraffin-embedded tumor tissue samples are analyzed for ERCC1 tumor expression by IHC and single-nucleotide polymorphisms.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed advanced invasive ovarian epithelial carcinoma, fallopian tube adenocarcinoma, or primary peritoneal carcinoma
* Has undergone optimal surgical staging
* Has received chemotherapy on either GOG-0172 or GOG-0182
* Adequate blood or DNA available for ERCC1 analysis
* Adequate tumor on paraffin-embedded tissue for IHC staining

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
Home Hospital for Bariatric Sleeve Gastrectomy

Providing acute care at home for medicine patients is a well-studied care model. Providing acute care at home immediately following major surgery is less well understood. The investigators seek to demonstrate the noninferiority of care at home versus the hospital for patients undergoing bariatric sleeve gastrectomy.


Eligibility Criteria:
Inclusion Criteria:

* All existing home hospital criteria apply, with the following taking precedent for this specific condition
* 21-55 years old
* Indication for bariatric laparoscopic sleeve gastrectomy per surgeon
* Caregiver capable of communicating with the home hospital team and able to stay in the same home as the patient the first night the patient is home

Exclusion Criteria:

* All existing home hospital criteria apply, with the following taking precedent for this specific condition
* Comorbidities

  * Body mass index\>55
  * Chronic kidney disease
  * Heart failure
* History of

  * Chronic pain (with or without opioid use)
  * Substance use disorder
  * Venous thromboembolism
  * Stroke
  * Chronic headache
* Medications

  * Anticoagulants and anti-platelets: aspirin, clopidogrel, warfarin, and direct oral anticoagulants
  * Beta blockade
  * Immunosuppressive
  * Supplemental oxygen
* Allergy to ketorolac
* Prolonged QTc
Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A

Study efficacy of everolimus on course of uveitis:

* obtain quiescence of inflammation after start of treatment
* duration to obtain quiescence of inflammation
* number of patients with quiescence of inflammation

occurence of new complications from uveitis

* course of visual acuity (LogMAR): percentage of patients with visual loss of 10 or more numbers on ETDRS as compared to baseline
* change of recurrence rate as compared to time before everolimus treatment
* occurence of recurrence after obtaining remission with everolimus treatment
* duration to occurence of recurrence o number of patients with recurrence
* corticosparing effect from everolimus
* number of patients without topical corticosteroids; number of patients with reduced topical corticosteroids (\<3x/daily)
* number of patients without systemic corticosteroids; number of patients with reduced systemic corticosteroids (\<10mg/daily)
* efficacy of uveitis within 12 months
* maintenance of remission after withdrawel of everolimus treatment at 12 months o course of cystoid macula edema (FLA, OCT)

Eligibility Criteria:
Inclusion Criteria:

* endogenous intermediate or posterior uveitis
* no quiesence in previous 3 months under systemic and topical steroids or systemic cyclosporine A
* indication for steroid sparing therapy
* uveitis related vision threating complications
* negative pregnancy test
* effective contraception

Exclusion Criteria:

Ophthalmic parameters:

* silicone oil in anterior chamber of both eyes para- or intraocular corticosteroid injections within previous 8 weeks
* opacities of optic media that obscure visualization of anterior or posterior eye segments

General parameters:

* requirement for combined immunosuppression for systemic immune-mediated disease contraindication against everolimus or cyclosporine A
* positive tuberculine test (GT 10
* currently immunosuppressive therapy with immunosuppressive drug other than cyclosporine
* poor compliance
* known intolerance to medication
A Study of Gene Polymorphisms Associated With Specific Presentations of Sexual Addiction

The study is intended to identify gene polymorphisms significantly associated with specific behavioral- and preoccupation-typologies of sexual addiction, and to identify additional potential genetic markers of sexual addiction. Research subjects with sexual addiction will be identified from the out-patient and in-patient populations of the investigative sites. Research subjects in the Control Group will be identified from the general population and from the student body of selected colleges. Approximately 1100 subjects will be enrolled in the study. Anticipating 10% drop-out, this is intended to generate a population of approximately 500 men and women clinically diagnosed with sexual addiction, and approximately 500 healthy men and women who do not meet diagnostic criteria for sexual addiction nor have psychopathology who will serve as the control population.


Eligibility Criteria:
Inclusion Criteria:

* Sexual Addict Group

Age \>= 18 years

Participating in sexual addiction treatment program

Sexual Addiction Screening Test--Revised (SAST-R) score \>= 11

Meets at least 3 diagnostic criteria for sexual addiction

* Control Group

Age \>= 18 years

SAST-R score \< 6

Exclusion Criteria:

* Sexual Addiction Group

Serious mental illness

Significant cognitive impairment

* Control Group

History of addiction

Current or previous Diagnostic and Statistical Manual (DSM-5) diagnosis

Serious mental illness

Significant cognitive impairment